Drug Trial Radar · NCT07265622
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 12, 2025
Primary completion
Jul 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first-in-human study of 7MW4911 in Chinese patients, to investigate its prelimary safety and efficacy in patients with Advanced Solid Tumors.
Conditions
- Solid Tumors
Interventions
7MW4911Drug
7MW4911 for IV infusion of various dose strengths administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and rates of adverse eventsTime frame: Up to approximately 2 years
- Maximum tolerated dose (MTD), recommended expansion dose (RED) and the recommended phase II dose (RP2D)Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.